Achieve Life Sciences Says Cytisinicline NDA Submission To FDA Planned For June 2025
April 21 (Reuters) - Achieve Life Sciences Inc ACHV.O:
ACHIEVE LIFE SCIENCES ANNOUNCES CYTISINICLINE PHASE 3 ORCA-3 TRIAL PUBLICATION ON SMOKING CESSATION IN JAMA INTERNAL MEDICINE
ACHIEVE LIFE SCIENCES INC - CYTISINICLINE NDA SUBMISSION TO FDA PLANNED FOR JUNE 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

Nvidia Stock: Breaking Down Its Key Risk and Why It’s Still a Compelling Buy in 2026

Vanguard ETF Could Beat the S&P 500 Again in 2026 —— Why Investors Are Paying Attention

Dell Stock Analysis: Is It Still Undervalued and the Best AI Infrastructure Play by 2026?

Is Novo Nordisk Positioned for Recovery in 2026 Amid Rising Competition and AI Innovations?

Tradingkey






